+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Drug Screening Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797904
The global drug screening market value was USD 7 billion in 2022, driven by the increasing prevalence of drug abuse across the globe. The market size is anticipated to grow at a CAGR of 13.8% during the forecast period of 2023-2031 to achieve a value of USD 22.5 billion by 2031.

Drug Screening Introduction

Drug screening is the process of detecting the presence of illicit drugs or their metabolites in biological samples, such as blood, urine, saliva, or hair. It plays a crucial role in various settings, including workplace drug testing, pre-employment screening, law enforcement, sports doping control, and clinical toxicology. The global drug screening market encompasses a wide range of products and services, including analytical instruments, rapid testing devices, consumables, and laboratory services.

Drug Screening Market Scenario

The global drug screening market has experienced substantial growth in recent years, driven by factors such as the increasing prevalence of drug abuse, rising awareness about the negative consequences of substance use, and growing emphasis on workplace safety. Furthermore, advancements in drug testing technologies, the development of novel drug screening products, and supportive regulatory policies have contributed to the market's expansion.

North America: The largest market for drug screening, driven by factors such as the high prevalence of substance abuse, advanced healthcare infrastructure, and a strong focus on research and development.

Europe: The second-largest market, with increasing demand for drug screening products and services due to a growing awareness of the importance of drug testing and a supportive regulatory framework.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly growing population, increasing prevalence of substance abuse, and growing investments in healthcare infrastructure.

Drug Screening Market Segmentations

Market Breakup by Product and Services

  • Drug Screening Services

Drug Screening Products

  • Analytical Instruments
  • Breathalyzers
  • Law Enforcement Agencies Breathalyzers
  • Fuel Cell Breathalyzers
  • Semi-Conductor Breathalyzers
  • Others
  • Immunoassay Analyzers
  • Chromatography Instruments

Rapid Testing Devices (RTD)

  • Urine Testing Devices
  • Drug Testing Cups
  • Dip Cards
  • Drug Testing Cassettes
  • Oral Fluid Testing Devices


  • Assay Kits
  • Sample Collection Devices
  • Calibrators & Controllers
  • Others

Market Breakup by End User

  • Workplace and Schools
  • Criminal Justice Systems and Law Enforcement Agencies
  • Drug Testing Laboratories
  • Drug Treatment Centers
  • Hospitals
  • Personal Users
  • Pain Management Centers
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Drug Screening Market

Some key trends of the market are as follows:
  • Growing adoption of rapid testing devices: There is an increasing demand for rapid, on-site drug testing devices, such as lateral flow immunoassays and oral fluid testing kits, due to their ease of use, quick results, and non-invasive sample collection methods
  • Advancements in drug testing technologies: The development of innovative drug testing technologies, such as liquid chromatography-mass spectrometry (LC-MS) and high-resolution mass spectrometry (HRMS), has improved the sensitivity, specificity, and efficiency of drug screening processes
  • Expansion of drug testing in the workplace: The growing emphasis on workplace safety and the enforcement of stringent drug testing regulations have resulted in a higher demand for drug screening products and services in the corporate sector

Drug Screening Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • LabCorp
  • Quest Diagnostics
  • Abbott
  • Thermo Fisher Scientific, Inc
  • Alfa Scientific Designs, Inc
  • OraSure Technologies, Inc
  • Siemens
  • F. Hoffmann-La Roche Ltd
  • MPD Inc
  • Shimadzu Corporation
  • Lifeloc Technologies, Inc
  • Drägerwerk AG & Co. KGaA
  • Premier Biotech, Inc
  • Omega Laboratories, Inc
  • Psychemedics Corporation
  • Clinical Reference Laboratory Inc.,
  • American Bio Medica Corporation
  • ACM Global Laboratories
  • Sciteck, Inc
  • Synens SAS

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Drug Screening Market Overview
3.1 Global Drug Screening Market Historical Value (2016-2022)
3.2 Global Drug Screening Market Forecast Value (2023-2031)
4 Global Drug Screening Market Landscape
4.1 Global Drug Screening Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Drug Screening Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by End User
4.2.3 Analysis by Region
5 Global Drug Screening Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Drug Screening Market Segmentation
6.1 Global Drug Screening Market, by Product and Services
6.1.1 Market Overview
6.1.2 Drug Screening Services
6.1.3 Drug Screening Products Analytical Instruments Breathalyzers Law Enforcement Agencies Breathalyzers Fuel Cell Breathalyzers Semi-Conductor Breathalyzers Others Immunoassay Analyzers Chromatography Instruments
6.1.4 Rapid Testing Devices (RTD) Urine Testing Devices Drug Testing Cups Dip Cards Drug Testing Cassettes
6.1.5 Oral Fluid Testing Devices
6.1.6 Consumables Assay Kits Sample Collection Devices Calibrators & Controllers Others
6.2 Global Drug Screening Market, by End User
6.2.1 Market Overview
6.2.2 Workplace and Schools
6.2.3 Criminal Justice Systems and Law Enforcement Agencies
6.2.4 Drug Testing Laboratories
6.2.5 Drug Treatment Centers
6.2.6 Hospitals
6.2.7 Personal Users
6.2.8 Pain Management Centers
6.2.9 Others
6.3 Global Drug Screening Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Drug Screening Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Drug Screening Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Drug Screening Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Drug Screening Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Drug Screening Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.2 US FDA
16.3 EU EMA
16.6 Others
17 Supplier Landscape
17.1 LabCorp
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Quest Diagnostics
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Abbott
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Thermo Fisher Scientific, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Alfa Scientific Designs, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 OraSure Technologies, Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Siemens
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 F. Hoffmann-La Roche Ltd
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 MPD Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Shimadzu Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Lifeloc Technologies, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Drägerwerk AG & Co. KGaA
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Premier Biotech, Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Omega Laboratories, Inc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Psychemedics Corporation
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Clinical Reference Laboratory Inc.,
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 American Bio Medica Corporation
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 ACM Global Laboratories
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Sciteck, Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Synens SAS
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
18 Global Drug Screening Market- Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Pricing Models and Strategies (Additional Insight)
21.1 Overview
21.2 Cost Model
21.2.1 Manufacturing Cost Analysis
21.2.2 Procurement Cost Analysis
21.2.3 Clinical Trial Cost Factors
21.3 Pricing Strategies
21.3.1 Competitor Pricing Analysis
21.3.2 Key Assessment of Product Attributes
21.3.3 Pricing Benchmark

Companies Mentioned

  • Labcorp
  • Quest Diagnostics
  • Abbott
  • Thermo Fisher Scientific, Inc.
  • Alfa Scientific Designs, Inc.
  • Orasure Technologies, Inc.
  • Siemens
  • F. Hoffmann-La Roche Ltd
  • Mpd Inc.
  • Shimadzu Corporation
  • Lifeloc Technologies, Inc.
  • Drägerwerk AG & Co. Kgaa
  • Premier Biotech, Inc.
  • Omega Laboratories, Inc.
  • Psychemedics Corporation
  • Clinical Reference Laboratory Inc.
  • American Bio Medica Corporation
  • Acm Global Laboratories
  • Sciteck, Inc.
  • Synens Sas



Table Information